Arrowhead reports a 73% mean reduction in CSF total tau with ARO-MAPT in healthy volunteers, supporting further study of its investigational RNAi therapy.
Written By: Aasritha Thippavajjala, PharmD
Reviewed By: Pharmacally Editorial Team
Arrowhead Pharmaceuticals reported interim results on October 14, 2026, from an ongoing Phase 1/2a study of ARO-MAPT, an investigational RNA interference (RNAi) therapy being developed for Alzheimer’s disease and other tauopathies. In healthy volunteers, the highest-dose group showed a mean 73% reduction in cerebrospinal fluid (CSF) total tau at Day 105, with a maximum individual reduction of 85%. The findings provide early clinical evidence of sustained tau lowering following subcutaneous administration, although their therapeutic significance remains undetermined.
Targeting Tau Production
ARO-MAPT is designed to silence the microtubule-associated protein tau (MAPT) gene in the central nervous system, reducing production of all six tau isoforms. Abnormal tau accumulation and aggregation are associated with several neurodegenerative disorders, including Alzheimer’s disease, MAPT-related frontotemporal dementia and progressive supranuclear palsy.
The therapy uses Arrowhead’s Targeted RNAi Molecule (TRiM) platform. The company described the interim findings as the first clinical validation of its platform for delivering small interfering RNA across the blood-brain barrier. However, the reported biomarker changes do not independently establish drug concentrations in brain tissue or demonstrate an effect on disease progression.
Phase 1/2a Trial Design
The placebo-controlled study, AROMAPT-SC-1001 (NCT07221344), evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of ARO-MAPT. The trial plans to enroll approximately 112 participants, including 64 healthy volunteers and up to 48 participants with early Alzheimer’s disease, defined as mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia.
The study includes single- and multiple-dose cohorts, with participants receiving ARO-MAPT or placebo through subcutaneous injection. Depending on the study part, participants may receive up to five doses. The interim tau results reported so far are from healthy volunteers, not participants with Alzheimer’s disease.
Interim Data Show Sustained Tau Reduction
Arrowhead reported the following mean reductions in CSF total tau at Day 105:
- 2.1 mg/kg: 40% reduction following administration on Days 1, 8 and 15.
- 6.4 mg/kg: 69% reduction following administration on Days 1, 8 and 15.
- 12.8 mg/kg: 73% reduction following administration on Days 1 and 15.
In the highest-dose group, the Day 105 measurement was obtained 90 days after the final administration. Arrowhead said the sustained reduction supports the potential for dosing every three months or less frequently. However, the reported results do not establish the efficacy or safety of a specific quarterly maintenance regimen.
The announcement does not provide participant numbers for each dose group, confidence intervals, p-values or sufficient detail about the reference used to calculate the reported percentage reductions. These omissions limit assessment of the precision and comparability of the estimates.
CSF total tau and other tau biomarkers are exploratory measures in the study materials. A reduction in CSF total tau is evidence of biomarker activity, but it does not necessarily establish a corresponding reduction in pathological tau aggregates or improvement in clinical outcomes.
Safety and Tolerability
Arrowhead described ARO-MAPT as generally well tolerated. Most treatment-emergent adverse events were mild or Grade 1. The company reported no serious treatment-emergent adverse events, deaths, treatment-emergent adverse events leading to treatment or study discontinuation, or persistent anaemia or neurobehavioural adverse events.
The most common events included injection-site reactions, vessel puncture-site bruising, upper respiratory tract infection, back pain and headache. Further data will be needed to characterise the safety profile across dose groups and in patients with Alzheimer’s disease.
Future Directions
All healthy-volunteer cohorts are fully enrolled. Arrowhead plans to complete dosing in the multiple-ascending-dose healthy-volunteer cohorts and continue enrolling participants with early Alzheimer’s disease. Further data updates are expected in 2027. The company has also initiated regulatory discussions ahead of planned studies in MAPT-associated frontotemporal dementia and progressive supranuclear palsy.
Clinical Interpretation
The 73% mean reduction in CSF total tau at Day 105 provides preliminary evidence that ARO-MAPT can produce a substantial and sustained biomarker effect after subcutaneous administration. Whether this effect translates into changes in brain tau pathology, cognition, daily function or disease progression remains unknown. Results from participants with Alzheimer’s disease, longer follow-up and fuller statistical reporting will be important in determining whether tau lowering offers a meaningful therapeutic benefit.
Reference
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers, Arrowhead Pharmaceuticals, 14 October 2026
Study of ARO-MAPT-SC in Healthy Participants and Participants with Early Alzheimer’s Disease, ClinicalTrials.gov ID NCT07221344
About the Writer
Aasritha Thippavajjala (Linkedin) is a pharm D student and aspiring medical writer with medical writing, clinical training experience and a strong interest in clinical research and patient safety She has hands-on exposure to clinical pharmacy activities including medication profile assessment, clinical case review, identification of potential drug-related problems, ADR awareness, patient counselling, and clinical documentation. She has also gained experience in medical literature review, evidence synthesis, and scientific communication through her published review article on digital twin-based patient simulation and her poster presentation at the 74th Indian Pharmaceutical Congress. Certified in ICH Good Clinical Practice (E6(R3)) and Scientific Writing in Health Research, she is passionate about applying her clinical knowledge and research skills to medical writing ,clinical research and contributing to accurate, evidence-based healthcare.